VIVOS THERAPEUTICS, INC. (VVOS) Total liabilities 2019–2025
VIVOS THERAPEUTICS, INC. (VVOS) total liabilities at each fiscal year-end, per SEC filings.
$26.7MFY2025 · since FY2019: $9.2M → $26.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $26.7M | +264.3% |
| FY2024 | $7.3M | -29.0% |
| FY2023 | $10.3M | +15.7% |
| FY2022 | $8.9M | +9.4% |
| FY2021 | $8.2M | -3.1% |
| FY2020 | $8.4M | -8.4% |
| FY2019 | $9.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VVOS financial trends
VVOS RevenueVVOS Net incomeVVOS Net marginVVOS Gross profitVVOS Gross marginVVOS Operating incomeVVOS Operating marginVVOS Operating cash flowVVOS Free cash flowVVOS Capital expendituresVVOS Return on equityVVOS Stock buybacksVVOS Dividends paidVVOS Total assetsVVOS Shareholders’ equityVVOS overview →